Amneal Announces Full Study Population Interim Phase 4 ELEVATE-PD Results, Reinforcing Previously Reported Benefits of CREXONT® in Parkinson's Disease
Amneal Pharmaceuticals announced positive interim results from its Phase 4 ELEVATE-PD study evaluating CREXONT®, an extended-release carbidopa/levodopa therapy for Parkinson's disease. The study of 214 patients showed significant increases in daily "Good On" time, reductions in "Off" time, and improved motor function, reinforcing prior Phase 3 find…